BioLeaders Edging Ahead In Dysplasia Therapeutics
This article was originally published in PharmAsia News
South Korea’s BioLeaders is making solid progress with its pipeline projects for dysplasia, preparing to begin a global Phase III trial with an oral immunotherapy, and adding a new domestic partner to a 2013 global licensing deal for an oral therapeutic vaccine.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.